Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
New Presentation slides.
http://www.agexinc.com/wp-content/uploads/2018/01/Biotech_Showcase_Jan_9_2018.pdf
"Significant potential milestones anticipated in next 12-24 months including planned distribution of shares and public listing"
Can't wait for the Brown Fat therapy to be approved. That one will be a massive hit. Obesity is a heck of a condition in the developed world, and probably over 50% of all the population suffers from. I can imagine every person over 40 getting regular brown fat injections every several years...
Who wouldn't want to pay to regain the metabolism of a 15-year-old, in a safe manner?
That will be the end of Diabetics. more or less.
Amazing.
They’re using Computing power to find known molecules with Regenerative capability.
They found known approved molecule with already known safety profile and off patent.
They’ll patent it and move quickly to test it off of prior tests, time & money.
Nothing immediate, but very good value creation.
Wise. Very wise.
Perhaps because the survey calls for 2018. we might not see massive rise that soon. But further along... a whole different story.
AGEX VIDEO OUT. WATCH IT.
It's coming. Psoriasis is a very difficult target. If they manage to meet primary goals, wow, prepare for a massive rocket ride. If not, it's going to be a drop to a very low level without B partnership...
Up 3$ since their sell, sell, sell call. Safe, but dumb.
In the meanwhile, it is safe to say the market gained understanding about how ATVI, as a business, is really a changed creature from the days of selling one time hackable CD's via expensive distributors.
Overwatch league is starting in 10th January and sponsors are paying up.
Revenue shifted from new games to new episodes in a game and microtransactions as repeat business.
New mobile games are being created.
If you want to understand WHY ATVI is so great an investment, just take the time to calculate what is the Net Tangible Asset (actual property used to generate profit) and then, compare that to EBIT. They use ~ 258 million (half of EA) PPE to generate 1.41 Bill. Ebit (which does not include the full yearly subscriptions, next month;s microtransactions and includes amortization that arguably is too agressive for assets that last >20 years in some cases. in this aspects they are way better than NFLX and among the top of the FAANG stocks. In other words, they PRINT cash, and GOBS of it. No wonder they were ready to take out Vivendy and shrink their share count.
The best?
They are just starting now.
There is so much to like here, and yet most people will try to earn a buck here, a buck there trading.
I guess that is why we never hear about billionairs that became so by trading.
$ATVI is going to be >> 10 Bagger from 10$, and smart investors (but not traders) will make millions in the process.
Links:
https://finance.yahoo.com/m/36a75bd6-0286-3d2d-939f-576fefa7b298/how-activision%27s-overwatch.html
https://finance.yahoo.com/news/activision-blizzard-inc-stock-could-151446451.html
https://finance.yahoo.com/m/bb5af975-de97-3443-afaa-989f6a9cf48a/the-tech-stocks-that-intend.html
https://finance.yahoo.com/m/b5ced8e2-c162-3960-a49c-df3bbf549077/exclusive-video%3A-activision.html
REGINA, Dec. 6, 2017 /CNW/ - Input Capital Corp. ("Input" or the "Company") (TSX Venture: INP) (US: INPCF) has released its year end results for the 2017 fiscal year. All figures are presented in Canadian dollars.
"Fiscal 2017 has been a profitable year of growth and expansion in many areas for Input Capital," said President & CEO Doug Emsley. "Not only did we successfully launch our new marketing stream, we expanded our client base by 168%, grew capital deployed by 42%, increased adjusted streaming sales by 37%, increased adjusted EBITDA by 16%, initiated a quarterly dividend, and became a Canadian Grain Commission licensed and bonded grain dealer.
"We are very excited about marketing streams because they require less upfront capital, have higher returns with less risk to Input, and are designed to help every farmer improve their bottom line. Combined with capital streams, they represent what Input Capital is all about – helping farmers improve their bottom lines by improving working capital and canola marketing opportunities."
FY2017 FULL YEAR HIGHLIGHTS
Adjusted streaming sales1 of $35.767 million on the delivery of 75,285 canola equivalent metric tonnes1 ("MT" or "tonnes") at an average price of $475 per MT. This is an increase in adjusted streaming sales of 37% and a volume increase of 40% compared to the previous comparable twelve month period (all full year highlights below are compared to the previous comparable twelve month period);
Cash operating margin1 of $26.196 million (up 16% over the comparable period last year), or $347.96 per MT (73.24% cash operating margin). Cash operating margin per MT is lower than last year due to the first sales of tonnes from marketing streams, which feature lower nominal cash margins than capital streams. As marketing streams grow as a percentage of Input's portfolio, management expects the cash operating margin to decline on a per tonne basis, but grow in total dollar amounts;
Adjusted operating cash flow1 of $18.773 million or $0.23 per share. This is an increase of 1% compared to last year and is in line with management's expectations for the year;
Adjusted net income1 of $1.792 million, or $0.02 per share. This is a decline of 29% from last year and is a result of planned investments made in client acquisition and the launch of marketing streams, positioning the company for strong future growth.
Recorded gross capital deployment of $36.794 million in upfront payments into 195 streaming contracts, adding 128 new producers to the portfolio and more than 307,000 MT to the Company's future canola sales. This is an increase of 42% in capital deployed and a 168% increase in streaming clients over the same period last year. Canola reserves have increased by 56% year over year;
In January 2017, Input soft-launched Marketing Streams, a new variation on streaming that targets farmers looking to get better pricing for their canola. By year-end, Input had signed over 190 marketing stream contracts with farmers, including more than 160 with new clients;
The Company received a grain dealer licence from the Canadian Grain Commission ("CGC") and is now licenced and bonded by the CGC, increasing Input's credibility and profile within the western Canadian agriculture marketplace and providing an additional level of assurance to farmers and other industry participants; and
In December 2016, Input initiated a quarterly dividend. It has made four dividend payments to date, paying out a total of $3.280 million to shareholders.
______________________________
1 Non-IFRS financial measures with no standardized meaning under IFRS. For further information and a detailed reconciliation, refer to "Non-IFRS Measures" beginning on page 27 of the MD&A.
FY2017 Q4 Highlights
Adjusted streaming sales1 of $13.681 million on the delivery of 28,799 canola equivalent metric tonnes ("MT" or "tonnes") at an average price of $475 per MT;
Generated an additional $0.786 million in sales from canola trading for total adjusted sales1 of $14.467 million;
Cash operating margin1 $7.110 million, or $247 per MT (51.97% cash operating margin);
Adjusted operating cash flow1 of $5.799 million or $0.07 per share;
Adjusted net income1 of $1.237 million, or $0.02 per share;
Recorded gross capital deployment of $1.751 million in upfront payments into 11 streaming contracts, adding 4 new producers to the portfolio and more than 10,000 MT to the Company's future canola sales;
On August 23, 2017, Input announced it retained Stonegate Capital Partners Inc. of Dallas, Texas to provide advisory and institutional outreach services in the United States;
On September 11, 2017, the Board of Directors declared a dividend of $0.01 per common share for the quarter ending September 30, 2017;
On September 28, 2017, Input President and CEO Doug Emsley presented at the Sidoti & Company Fall 2017 Conference in New York, and;
Finished the quarter with:
Cash of $17.615 million;
Total canola interests (current portion and long-term portion) and other financial assets (liabilities) (herein referred to collectively as "canola interests") of $68.423 million;
Multi-year active streaming contracts with 301 farm operators, up from 112 a year ago;
Total shareholders' equity of $105.119 million;
$6.351 million drawn on its $25 million revolving credit facility; and
No long-term debt.
_________________________________
1 Non-IFRS financial measures with no standardized meaning under IFRS. For further information and a detailed reconciliation, refer to "Non-IFRS Measures" beginning on page 27 of the MD&A.
KEY PERFORMANCE INDICATORS FOR THE COMPARABLE PERIODS ARE SUMMARIZED BELOW:
Selected non-IFRS measures1
Three months ended
Sep 30
Twelve months ended
Sep 30
CAD millions, unless otherwise noted
2017
2016
2017
2016
Adjusted streaming sales
13.681
7.656
35.767
26.044
Adjusted streaming volume (MT)
28,799
15,916
75,285
53,949
Average selling price from streaming contracts
$475.04
$481.03
$475.09
$482.75
Cash operating margin
7.110
6.514
26.196
22.548
Cash operating margin per tonne
$246.88
$409.27
$347.96
$417.95
Cash margin
1.991
1.835
7.403
7.803
Cash margin per tonne
$69.13
$115.29
$98.33
$144.64
Adjusted EBITDA
6.351
5.481
20.634
17.824
Adjusted EBITDA per share (basic)
$0.08
$0.07
$0.25
$0.22
Adjusted operating cash flow
5.799
5.891
18.773
18.480
Adjusted operating cash flow per share (basic)
$0.07
$0.07
$0.23
$0.23
Adjusted net income (loss)
1.237
0.550
1.792
2.256
Adjusted net income (loss) per share (basic)
$0.02
$0.01
$0.02
$0.03
Upfront payment per tonne2
$171.16*
$181.84
112.23*
280.49
*Upfront payment per tonne reflects upfront payments made into both Capital Streams and Marketing Streams. For more information about Marketing Streams, refer to discussion on Marketing Streams beginning on page 14 of the accompanying MD&A.
SALES
For the fiscal year ended September 30, 2017, Input generated adjusted sales from streaming contracts of $35.767 million on the adjusted streaming volume of 75,285 MT an average price of $475 per MT.
The sales from streaming tonnes plus net settlements from streaming tonnes for the twelve months ended September 30, 2017, represent a 40% increase in quarterly volume over the comparable period one year ago, when the Company sold 53,949 MT of canola equivalent for revenue of $26.044 million for an average price of $483 per MT.
For the quarter ended September 30, 2017, Input generated adjusted sales from streaming contracts of $13.681 million on adjusted streaming volume of 28,799 MT for an average price of $475 per MT.
The sales from streaming tonnes plus net settlements of canola interests for the quarter represent a significant increase in quarterly volume over the comparable quarter one year ago, when the Company sold 15,916 MT of canola equivalent for revenue of $7.656 million for an average price of $481 per MT.
___________________________
1 Non-IFRS financial measures with no standardized meaning under IFRS. For further information and a detailed reconciliation, refer to "Non-IFRS Measures" beginning on page 27 of the MD&A.
CAPITAL DEPLOYMENT AND STREAMING CONTRACT PORTFOLIO
Year to Date
For the fiscal year ended September 30, 2017, Input recorded gross capital deployment of $36.794 million (compared to $25.825 million in the same period last year) into 202 streaming contracts for the right to purchase more than 307,000 MT of canola over the life of the streaming contracts. Net deployment for accounting purposes was $32.507 million.
During the twelve months, Input added 189 new contracts; 134 in Saskatchewan, 52 in Alberta and 3 in Manitoba. The remaining contracts were renewals, expansions and of existing contracts. During the comparable twelve month period ended September 30, 2016, Input added 33 new producers to its portfolio.
During the twelve month period, Input's average upfront payment per tonne was $112.23 compared to $280.49 in the comparable period last year. The upfront payment per tonne reflects upfront payments made into Marketing Streams which are lower than Capital Streams, bringing the upfront payment per tonne down substantially.
As of September 30, 2017, Input's active streaming portfolio consisted of 301 geographically diversified streams. 221 of the Company's canola streams are with farms in Saskatchewan, 71 are located in Alberta, and 9 are in Manitoba. The Company is pleased with its continued growth across Alberta and Saskatchewan over the last year and expects to continue diversifying its asset base across the Prairies in FY2018 as it continues to add new streams to its portfolio.
The change in active streaming contracts by region on a quarterly and annual basis is demonstrated in the table below:
Active Streaming
Contracts
Sep 30, 2017
Jun 30, 2017
Quarterly
Growth
Sep 30, 2016
Year Over Year
Growth
Manitoba
9
9
-
6
3
Saskatchewan
221
220
1
87
134
Alberta
71
71
-
19
52
Total
301
300
1
112
189
Quarter Ended September 30
The quarter ended September 30 is always the slowing period of the year for capital deployment. For the three months ended September 30, 2017, Input recorded gross capital deployment of $1.751 million (compared to $1.784 million in the same quarter last year) in upfront payments into 11 streaming contracts for the right to purchase over 10,000 MT of canola over the life of the streaming contracts.
During the quarter, Input added four new producers to its streaming contract portfolio; all of them in Saskatchewan. The remaining contracts were renewals, expansions and restructures of existing contracts.
During the comparable quarter last year, Input added five new producers to its portfolio.
During the quarter, Input's average upfront payment per tonne was $171.16 compared to $181.84 in the comparable quarter last year. The upfront payment per tonne reflects upfront payments made into Marketing Streams which are lower than Capital Streams, bringing the upfront payment per tonne down substantially. As a result, Input now controls more physical canola per dollar invested than at any time in its history. For more information about Marketing Streams, refer to discussion on Marketing Streams beginning on page 14 of the MD&A.
BALANCE SHEET
Key balance sheet items are summarized below:
Statements of Financial Position
CAD millions, unless otherwise noted
As at
Sep 30, 2017
As at
Sep 30, 2016
Cash
17.615
16.643
Canola interests and other financial assets
68.423
77.757
Total assets
120.555
118.548
Total liabilities
15.436
2.935
Total shareholders' equity
105.119
115.613
Working capital
28.870
71.181
Revolving credit facility
6.351
-
Long-term debt
-
-
OUTLOOK
This is the time of year when the level of activity at Input picks up substantially versus the quiet summer months. Input's business is highly seasonal, both in terms of when the Company signs up new clients and deploys capital (starting in October and building slowly to a climax in February through June), and in terms of when it receives canola deliveries and records revenue (starting in August or September, depending on the pace of harvest, and running through to the end of March).
Except for farmers in the area of southern Saskatchewan that was very dry this year, prairie farmers generally had a good growing season in 2017 featuring a combination of good yields, strong prices, and smooth harvest weather conditions. These factors have contributed to good near-term liquidity for farmers and has the potential to contribute to lower demand for the Company's capital streams. On the other hand, confident farmers tend to expand, and management has previously found farmers who are expanding to represent a good market for capital streams. It is too soon to predict which will be the dominant outcome this year.
As a result, management has discontinued the practice of providing guidance regarding annual capital deployment. Management's objectives for the year are to continue growing its client base by deploying capital into both capital and marketing streams, and to do so at a level which is greater than the previous year's capital deployment. Since its founding in 2012, Input has grown its annual capital deployment by a Compound Annual Growth Rate (CAGR) of about 18% and management plans to continue to grow deployment year-over-year.
WEBCAST AND CONFERENCE CALL DETAILS
A conference call will be held on Thursday, December 7, 2017 starting at 9:30 am Saskatchewan time (10:30 am Eastern time) to further discuss the year end results. To participate in the conference call use the following dial-in number:
Participant Dial in #: (888) 231-8191 (North America Toll Free)
Participant Dial in #: (647) 427-7450 (International)
Webcast URL: http://event.on24.com/r.htm?e=1532066&s=1&k=E98FCDAEBA3F1A4CF142138CBA27681C
It is recommended that participants dial in five minutes prior to the commencement of the conference call. Soon after the completion of the call, the webcast will be available for download on the Input Capital website at investor.inputcapital.com.
Check out slide 6 in this deck about ISCO
New slides
BioTime (BTX) Presents At The 10th Annual LD Micro Conference 2017 - Slideshow $BTXhttp://www.seekingalpha.com/article/4130108
Patrick Cox is the wrong person to draw reassurance from.
While I’m long, and excited about the future, Patrick’s lucky he does not have to live off his own investment rec’s, because he tend to picks losers, bankruptcies candidates, and has no idea about management or finances that make or brake a business.
Hopefully this one rec will save his reputation.
http://www.stonegateinc.com/reports/INP_Initiation_Nov_2017_Final.pdf
It appears 2017 FY will show lowered Rev and a loss.
Not conducive to higher PPS, but the opposite.
Marketing streams of higher IRR good news, but since much smaller streams, unless deployment really picks up the total growth might come slow.
So, rough several quarter ahead.
INP’s IR firm publishes coverage
Thanks Ahab.
I am very curious to see how they attempt to market Renevia, and what sort of sales trajectory it will have at first.
If it does well, overnight BTX becomes an operational entity with some real CF for evaluation purposes and credibility increases.
That’s going to have significant implications on valuation.
I don’t quite follow the rant, but I was thinking how great and liberating this development would be for 35+ women who delayed getting pregnant and now find they can’t conceive due to the deterioration of egg quality.
Anyway thanks for the contribution to the discussion.
https://www.technologyreview.com/s/603343/eggs-from-skin-cells-heres-why-the-next-fertility-technology-will-open-pandoras-box/
http://stm.sciencemag.org/content/9/372/eaag2959
It is established science that skin cells can be turned into beating heart muscle.
Since the largest shareholder is Biotime, the discussion is there.
Terry asked:
BTX Sub Asterias Highlights (Conf Call).
-> Market Opportunity for OPC1:
"Previously published data from key opinion leaders in the spinal cord injury field have shown that the two motor level improvement in hand or in finger function that we're targeting in the SCiSTAR trial which as Mike mentioned earlier can be driven by only four-centimeter long restoration of conduction. Can drive substantial improvements for these patients in independence, quality of life, employability and lifetime cost of care. As a result, we estimate that the market potential for OPC1 is substantial and asset of $1 billion annually in the United States alone."
-> The 10 Million Cell AIS-A cohort is still stable and improving (safe and effective) (at 12 months target was to get at least two motor levels on at least one side, in practice results were 67% 4/6).
"Our previous efficacy data readout from the SCiSTAR show a promising motor function recovery at three months with maintained or additional improvement observed through six and nine months post-treatment for subjects in the AIS- A 10 million cell cohort or Cohort 2 of the study.
We are very pleased to see that the longer term data continues to convincing results. And we believe shows OPC1's potential will generate durable clinical benefit for patients with severe spinal cord injuries. In October, we reported positive 12-month follow-up data from the cohort. Specifically, the result showed, that previously reported meaningful improvements in arm, hand and finger function have been sustained and in some cases further improved at 12-month following administration of OPC1."
-> Cohorts 3+4 done, 5 - halfway to completion.
"During the third quarter, we completed enrollment and dosing Cohorts 3 and 4 and we're now more than halfway done with enrollment of the fifth and final cohort."
-> Cohorts 3+4 data is coming (Q1 - 6M update) and it is getting exciting (its here that we might see surprising results as the dosage is higher and the scope of injury is less severe than in cohorts 1+2).
"We expect to provide six months readout from Cohorts 3 and 4 in the first quarter of 2018 and 12 months readout during the third quarter of 2018. This is an important development for Asterias."
-> FDA Granted Regenerative Medicine Advanced Therapy (RMAT) to OPC1, is validating.
"The FDA granted OPC1 the Regenerative Medicine Advanced Therapy or RMAT designation is an expedited program established under 21st Century Cures Act to walk through the development and approval of important new regenerative medicine therapies intended for the treatment of serious of life-threatening diseases and conditions. We're gratified by the FDA's interest in the therapeutic potential of OPC1 and greatly appreciate their decision to provide support to accelerate its regulatory review and potential approval."
-> next step is to formulate a PII trial.
-> 12m data has sparked interest from Japan (where regulation only calls for Safety data and leaves efficacy for the free market). Discussions are in progress.
"those discussions are definitely continuing to progress on - and we're in conversations with multiple parties and even into confidential [indiscernible] for some of them, following the 12-month data readout we've also had some additional inbound interest from new parties as well. So those discussions are making good progress as you know any business development relationship does that sometimes to secure, but we will definitely provide an update as their timeline."
-> Cost Cutting and cash management (BTX being the boss - their interests align with all investor - have the Sub use as little cash and generate as much progress!
"our monthly cash burn has been a little over $2 million recently and so we're taking that 40% hair cut off with that. So we actually think our cash burn for 2018 on average will be about $1.3 million per month. So we're looking at 2018 annual burn rate of between $15 million and $16 million."
-> RMAT designation under the new law is new, and no one knows what the FDA will want for approval. OPC1 is leading the approval race.
" it's too early to say exactly what FDA would require to ultimately achieve approval".
Conclusion: Nice and steady. good progress is made and in Q12018 we might be in for a nice surprize and great PR. imagine another story similar to what we saw in ASI A quadriplegic moving his hands. Good solid progress.
The market sure didn't like the delay nor the lack of guidance as to the new launch date.
I sure believe their response was the correct one. These things are variable no one can forecast around.
There was almost no analyst coverage in the call.
The stock dropped on a so-so volume (~130K, we've seen over 1M in June), which seems like a minor investor getting frustrated.
Nothing to see here, folks.
About Biotime's spin-off (and holding) Oncocyte's DetermaVu delay (Good news).
Problems with Supplier, and careful science with sufficient toold to track down and correct any variability in the tool itself. These things tend to happen in real life science and serious executives don't avoid their responsibility to correct any error when one is found.
"Our expectation was to complete this study during the fourth quarter. However, during the initial process of running samples for the clinical validation study, our technicians observed inconsistent analytic results. During our analysis of the results of the first samples of the validation study, we noticed some anomalous results with control or housekeeping markers. As well as the biomarkers in the tests that are used to identify whether or not a lung nodule is benign. We include a number of synthetic housekeeping markers that act as controls.
These synthetic biomarker controls are designed to be very stable and they're quantization should remain virtually identical across all tests. In this instance, we noticed that the measured levels of certain housekeeping markers varied significantly from expected levels, thereby revealing variability in the consumables that was not related to the test performance.
And consequently we believe that the inconsistent results were caused by a variance in a recently received lot of the consumables that are used in the processing system that analyzes blood samples. To address this issue, OncoCyte has ordered and is waiting to receive new lots of consumables from the supplier.
Once the new consumables are received, OncoCyte will conduct internal quality control procedures to ensure that they meet our requirements. Upon confirming that the new consumables will allow the analytic device to generate data with the consistency and precision required for DetermaVu, we will initiate the clinical validation study.
Due to the time required for these steps, OncoCyte now anticipates that completion of the clinical validation study necessary for the commercial launch of DetermaVu will be delayed into 2018 depending on the successful rectification of the causes of the inconsistent analytic results.
OncoCyte has only observed this issue in the most recent lot of consumables that we found problems with. Our earlier studies were conducted using different lots of consumables where this problem was not conserved. Consequently, the previous studies were not impacted by this issue and the positive results reported to date have not changed. The positive result seen in those studies are valid and repeating the earlier studies is not necessary and is not being considered."
Unlike what another poster wrote, the company does intend to leverage the results in Renevia to the Easthetic market. In fact, at the last conf. call Adi briefed that another trial is being conducted in California where Renevia is being administered to healthy patients for cosmetic purposes.
The logic is simple: the product really works and has much longer lasting results than the alternatives.
So - the product will probably be much better than Botox (when used with fat stem cells). As to its use alone? who knows. it's too early to tell but my gut feeling it will not be worse. and there is not too much cost of goods going into it, so if they decide, they can price it to be competitive against botox. we will see.
Timeline - everything will be in Europe first, and the data and experience will be used to clear with the FDA.
I do not expect it to be a big deal in terms of approval. its really already approved (same content).
There are so many other application for this stuff... They know it and want to keep control so the full spectrum of usage can be established.
But none will happen before next year when marketing starts.
Progress is being made.
We are nearing a point where revenue growth starts, and that is the time when the rest of the market is going to pay attention.
until then, patience is warranted.
Look at the recent investor slide - all data inside...
No. They are using MRI Interventions to deliver the Stem Cell therapy to the right section of the brain. If approved, the use of this instrument will be a part of the therapy. It’s a very interesting piece of information.
New trial: Additional indications for #Revevia starting.
Title: BioTime Announces First Patient in U.S. Clinical Trial Treated for Facial Volume.
First investigator-led trial of Premvia in U.S. for cosmetic use
Clinical trial being conducted by Dr. Aronowitz, a leading Beverly Hills-based Plastic Surgeon
ALAMEDA, Calif.--(BUSINESS WIRE)--Oct. 11, 2017-- BioTime, Inc. (NYSE American: BTX), a late stage clinical biotechnology company focused on developing and commercializing products addressing degenerative diseases, today reported that an investigator-led clinical trial has successfully treated its first patient in a study of PremviaTM as a carrier for stromal vascular fraction cells (SVF) for the treatment of age-related volume loss in the face. This is the first clinical trial to study PremviaTM in a purely cosmetic application. PremviaTM, which has 510(k) clearance in the U.S. for wound management, is expected to file for CE Mark in Europe under the name Renevia® for the treatment of facial lipoatrophy in HIV patients later this year.
The objective of this investigator-led study is to evaluate the safety and performance of PremviaTM as a carrier for autologous SVF in non-HIV patients. SVF cells are believed to contain fat tissue progenitors, and are prepared at the point of care from a lipoaspirate. This single-arm study is designed to evaluate 10 subjects who each receive a treatment of PremviaTM and SVF. The study's primary endpoint is mean change in volume of each side of the face from baseline six months post treatment, with secondary endpoints being hemi-facial volume change at one, two, three and 12 months from baseline.
"I am encouraged by the results seen in the EU pivotal study. Premvia has the potential to address the limitations that we see with autologous fat transfer," said Dr. Joel A. Aronowitz, a leading Beverly Hills-based plastic surgeon who is conducting the study. "My patients need additional options, and I am excited that Premvia may enhance fat transfer and could help provide long lasting, natural looking facial augmentation with higher volume retention."
HIV-associated lipoatrophy is a severe form of lipoatrophy characterized by the pathological loss of body fat from under the skin. In an EU pivotal clinical trial, Renevia® met its primary endpoint, and treated patients retained approximately 100% of transplanted volume at six months, based on 3-D volume measurement of the implanted area. In addition to meeting the primary endpoint, BioTime announced that treated patients retained an average 70% of the transplanted volume at 12 months and 64% at 18 months. While only a small number of patients have been observed through 18 months, the results thus far are encouraging and the long-term performance exceeded management expectations. All Renevia® transplants were shown to be well tolerated and there were no device-related serious adverse events noted during this trial.
The data in the trial has encouraged BioTime to make plans to seek additional indications for Renevia®, such as cosmetic facial aesthetics. BioTime expects to file the CE mark application by the end of this year with possible approval and launch next year.
$AgeX’s Aubrey de Grey.
Ok, Ok... He does looks like a Prepper from the mountains. I love his look. It says ‘look at me - I’m amazing!’
Aubrey de Grey, Ph.D. Is the VP of New Technology Discovery in AgeX, BTX.
He is one of the influential figures in the field of Aging research, and frequently appears in the media.
“Is Aging a Disease that Can be Cured?” with guest Aubrey de Grey
https://philosophyinpubliclife.org/2017/10/08/is-aging-a-disease-that-can-be-cured-with-guest-aubrey-de-grey/
It’s called “Time Arbitrage”.
Short the near term return, Long future returns.
Can be hard at first, but the only way to generate 10X, 20X, 100X on investment.
Not for traders, flippers, etc. obviously.
A safe (but dumb) bet to sell after 6X, recommended by people who do not understand what is compounding, don’t understand the impact on tax and are too short sighted.
https://www.cnbc.com/2017/10/09/analyst-downgrades-activision-on-risk-overwatch-esports-will-disappoint.html
ATVI might take a breather, but the next 2X from here will be 12X for INVESTORS, something traders can only dream about...
Murph, head to the company site, there’s great videos there explaining the innovative tech.
Make sure to understand this is an extremely early stage biotech that is likely to suffer price swings until done with phase 3.
Antibiotic of last resort - gone.
Scientists attending a recent meeting of the American Society for Microbiology reported they had uncovered a highly disturbing trend. They revealed that bacteria containing a gene known as mcr-1 – which confers resistance to the antibiotic colistin – had spread round the world at an alarming rate since its original discovery 18 months earlier. In one area of China, it was found that 25% of hospital patients now carried the gene.
Colistin is known as the “antibiotic of last resort”. In many parts of the world doctors have turned to its use because patients were no longer responding to any other antimicrobial agent. Now resistance to its use is spreading across the globe.
https://www.theguardian.com/society/2017/oct/08/world-faces-antibiotic-apocalypse-says-chief-medical-officer
Here are couple of facts to take into account.
A. Generally speaking, Wall Street is talking from 12 month’s view point. An individual’s investor’s advantage is he can buy with a longer time frame. There is little doubt absolutely nothing is happening here in the next couple of months, but by the time it does, Wall Street will be late to the party.
Example: I bought $ATVI at 10$, and held for about 5 years until the stock made ANY move. Wall Street was sell/hold. Today, at 60$+, analysts are piling in with Buy, but their return is much less than mine.
B. In most cases, Buy side analysts are focusing on a. Sufficiently large business (in terms of M. Cap) as microcaps cant accommodate large inflows of $ due to liquidity. b. As a service for fund raising to client (since they need to sell the stock issued). With Biotime, there is little reliance on Wall Street: it’s mostly funded by insiders, Directors who just hold the stock. So no analysts is retained to generate “hype”.
C. The Stem Cell biotech sector has a terrible record. There is no one company that made investors money. No one test to pass the FDA, nor any phase 3, 2. Dilution to zero is a common problem. In short, it’s a bitch trying to pitch an investor an idea about Stem Cell Medicine. Smart people “know “ it’s unproven territory.
As a result, the business is unfollowed and Investors (who got burned) are not watching.
Those that do, however, see the progress being made:
1. Several phase 1/2 - AST OPC, OpRegen progressing with fantastic results;
2. Several near term products about to hit the market within the next year or so: Oncocyte’s tests; Renevia.
3. Constant R&D generating more billion dollar opportunities (brown adipose Cell therapy at Agex, as an example)
4. Supreme financial dexterity: non dilutive financing such as grants from various sources, spinning off of daughter companies to shareholders and simplification of the financial reports.
I don’t care about the next 12 months. I believe BTX is easily a 15 billion dollar business in the next 10 years.
The reinvestment opportunities are amazing.
It is the Top Dog in the Stem Cell world, practically owning the Key IP in the embryonic sector.
It is the most advanced research wise.
It has the best heavily invested executives and board members.
It has an unbelievable back wind, mega trend propelling it: massive costs of treating the boomers + not enough funds to achieve this. Japan already stopped requiring efficiency tests in Stem Cell therapies, only safety, because their population is rapidly aging. The western world will have to follow, do the math.
Each on of these vectors can help. Together, they create what Charlie Munger refers to al lolapalooza effect.
And these companies?
You hold for a lifetime, as long as everything progresses as planned.
And progress is made.
I hope this helps.
Sorry, not too many traders around here. I spend months without looking at the daily chart...
I don’t think this name reacts well short term, other than buy below 2.5 and sell above 3.
For the time being, that is.
That could be the case.
What draws me to this business is the quality of management + them being major investors and the staggering, almost infinite number of therapies the Stem Cell platform (protected by Patents on IP) can generate.
This can create decades of rapid growth and is unique.
I’m watching many biotech companies but NON come close to this management team’s care and skill in finding funding without killing shareholders.
They get so much done in so little.
And soon they will be able to be profitable.
An amazing find for those with sufficient time horizons.
If you want to participate in this business potential success but without the risk of being diluted to nothing (as has been the practice), check out the microcap device company they use to place the Stem Cell therapeutic into the brain in Australia. For every procedure, they will need to pay ~7,500$...
Happy to see Reliq performing, for a little long position.
Seems like they finally managed to turn a pilot into an order that that is a massive show of approval by clients, further validating the platform.
Reliq still suffers from SERIOUS Corporate issues I discussed in prior posts without any sign of improvement.
In addition, Reliq financial condition is precipitous and much more dilution is coming before shareholders are rewarded (possibly the reason why our CEO is carefully keeping HER own money elsewhere than invested on Reliq Equity:
Curren liabilities - -1.42 M
Current Assets - 0.374
A deficit of over 1 M dollar.
plus:
S&M -0.22M
G&A - 1.03
R&D - 0.46
Operating -1.72
Well over 2 M D loss per annum.
At 70% Gross - you need about 3 M$ per Annum to BE, and that is before expense expansion comes when some revenues show up (bank on it).
These type of numbers usually translate into massive selling pressure on the stock.
Wait and see how our Hero CEO does another PP at 7 cents (she already did one and diluted the hell out of shareholders who were too starry-eyed to realize what she did (that is the controlling shareholders who brought her aboard and pay her salary).
They need to really scale up sales fast, mHealth is a HOT sector, and they do not yet have any competitive advantage that is not easily breached.
Dilution is coming and with it the inevitable stock drop.
a good trading pattern will be to sell here and wait for the stressed out funding to pummel the stock way lower before buying again.
Stay safe.
Hold on tight: Last step before DetermaVu (Oncocyte - BTX Sub) Commercializes (Last Quarter 2017)!
OncoCyte Announces Successful Completion of CLIA Lab Validation Study of its DetermaVu™ Lung Cancer Diagnostic Test; Clinical Validation Study Initiated DetermaVu™ Launch Planned for Fourth Quarter 2017
ALAMEDA, Calif., Sept. 27, 2017 (GLOBE NEWSWIRE) -- OncoCyte Corporation (NYSE American:OCX), a developer of novel, non-invasive, blood-based liquid biopsy tests to assist in the early detection of cancer, announced today that its CLIA laboratory has successfully completed a rigorous validation study of DetermaVu™, OncoCyte’s diagnostic test for lung cancer. In this study, OncoCyte assayed approximately 120 samples previously tested in its 299-patient study presented at the American Thoracic Society conference in May 2017, with the goal of demonstrating that OncoCyte’s new clinical laboratory provides the same results on clinical samples as those obtained in its R&D lab. The results met all performance criteria, demonstrating the accuracy and robustness of the assay as performed in the Company's CLIA laboratory. The CLIA lab validation study included specific protocols to confirm the accuracy, reproducibility, and precision/repeatability of DetermaVu™.
“The laboratory staff and procedures in place in the clinical laboratory have been confirmed to provide accurate, reliable, consistent and reproducible results,” said William Seltzer, PhD, FACMG, VP of Clinical Services and the Laboratory Director for OncoCyte. “The results were consistent with the positive data reported at the American Thoracic Society 2017 International Conference, and have enabled us to initiate our Clinical Validation Study, the final step prior to the commercial launch of DetermaVu™.”
The Clinical Validation Study has now begun and is expected to be completed in the fourth quarter of 2017. In this study, approximately 300 new blinded blood samples, which have been prospectively collected will be assayed in the CLIA lab using DetermaVu™. The performance of the test will be assessed against the clinical diagnosis of the patients from whom the samples were collected. If the Clinical Validation Study is successful and the results meet commercial requirements, OncoCyte will commence the commercial launch of DetermaVu™.
“Successful completion of the CLIA Lab Validation Study is another important step toward launching DetermaVu™,” said William Annett, President and Chief Executive Officer. “We plan to complete the ongoing Clinical Validation Study in the fourth quarter.”
OncoCyte believes that widespread utilization of DetermaVu™ could result in a substantial reduction in the number of unnecessary, expensive lung biopsies performed annually in the U.S., with a corresponding reduction in the surgical risk to patients undergoing biopsy procedures. Broad use of DetermaVu™ would result in a fundamental advancement in the diagnosis of suspicious lung nodules by allowing physicians to determine more accurately which patients need biopsies and which patients only need follow-up imaging. The Company estimates that approximately 1.4 million patients annually in the U.S. could benefit from the DetermaVu™ test. Depending on market penetration and reimbursable pricing, this could translate into a market opportunity of up to $4.7 billion annually.
About OncoCyte Corporation
OncoCyte is focused on the development and commercialization of novel, non-invasive blood and urine (“liquid biopsy”) diagnostic tests for the early detection of cancer to improve health outcomes through earlier diagnoses, to reduce the cost of care through the avoidance of more costly diagnostic procedures, including invasive biopsy and cystoscopic procedures, and to improve the quality of life for cancer patients. While current biopsy tests use invasive surgical procedures to provide tissue samples in order to determine if a tumor is benign or malignant, OncoCyte is developing a next generation of diagnostic tests that will be based on liquid biopsies using blood or urine samples. OncoCyte’s pipeline products are intended to be confirmatory diagnostics for detecting lung, breast and bladder cancer. OncoCyte’s diagnostic tests are being developed using proprietary sets of genetic and protein markers that differentially express in specific types of cancer.
DetermaVu is a trademark of OncoCyte Corporation.